PROMIS GH量表在卒中患者中的验证研究
本研究在1102例缺血性和出血性卒中患者中评估PROMIS GH量表的心理测量学特性,发现其具有可接受的内在一 reliability、良好的收敛效度和区分效度,支持将其作为卒中标准结局测量工具。
要点
- PROMIS GH在卒中患者中内部信度中等(ordinal α 0.82-0.88),两因子模型拟合边缘(RMSEA 0.11)。
- 所有PROMIS GH条目与PROMIS领域量表显著相关(P<0.001),收敛效度良好。
- PROMIS GH对mRS水平有优秀区分度,10个条目中8个效应量>0.5,响应性良好。
核心结论
- PROMIS GH在卒中患者中表现出可接受的测量性能,支持ICHOM推荐将其纳入卒中标准结局测量集。
研究设计与样本
- 研究纳入2015年10月12日至2017年6月2日在脑血管门诊就诊的1102例处于不同恢复阶段的缺血性和出血性卒中患者,电子收集PROMIS GH和6个PROMIS领域量表,进行验证性因子分析、重测信度和效度评估。
主要发现
- 内部信度中等(ordinal α 0.82-0.88),两因子模型拟合边缘(RMSEA 0.11)。
- 所有PROMIS GH条目与PROMIS领域量表显著相关(P<0.001)。
- 所有PROMIS GH条目和组分得分对mRS水平有优秀区分度。
- 10个PROMIS GH条目中8个显示良好响应性(效应量>0.5)。
- 信度和效度在卒中亚型和残疾水平(mRS<2 vs ≥2)间保持一致。
关键数值与推荐
- 内部信度:ordinal α 0.82-0.88。
- 模型拟合:RMSEA 0.11。
- 收敛效度:所有条目与PROMIS领域量表相关P<0.001。
- 响应性:10个条目中8个效应量>0.5。
临床怎么用
- 可将PROMIS GH作为卒中患者标准结局测量工具之一,用于评估全球健康相关生活质量。
- 在缺血性和出血性卒中患者以及不同残疾水平中均可使用PROMIS GH。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: The International Consortium for Health Outcomes Measurement recently included the 10-item PROMIS GH (Patient-Reported Outcomes Measurement Information System Global Health) scale as part of their recommended Standard Set of Stroke Outcome Measures. Before collection of PROMIS GH is broadly implemented, it is necessary to assess its performance in the stroke population. The objective of this study was to evaluate the psychometric properties of PROMIS GH in patients with ischemic stroke and intracerebral hemorrhage. METHODS: PROMIS GH and 6 PROMIS domain scales measuring same/similar constructs were electronically collected on 1102 patients with ischemic and hemorrhagic strokes at various stages of recovery from their stroke who were seen in a cerebrovascular clinic from October 12, 2015, through June 2, 2017. Confirmatory factor analysis was performed to evaluate the adequacy of 2-factor structure of component scores. Test-retest reliability and convergent validity of PROMIS GH items and component scores were assessed. Discriminant validity and responsiveness were compared between PROMIS GH and PROMIS domain scales measuring the same or related constructs. Analyses were repeated stratified by stroke subtype and modified Rankin Scale score <2 versus ≥2. RESULTS: There was moderate internal reliability (ordinal α, 0.82-0.88) and marginal model fit for the 2-factor solution for component scores (root mean square error of approximation, 0.11). Convergent validity was good with significant correlations between all PROMIS GH items and PROMIS domain scales (P<0.001 for all). There was excellent discrimination for all PROMIS GH items and component scores across modified Rankin Scale levels. Good responsiveness (effect size, >0.5) was demonstrated for 8 of the 10 PROMIS GH items. Reliability and validity remained consistent across stroke subtype and disability level (modified Rankin Scale, <2 versus ≥2). CONCLUSIONS: PROMIS GH exhibits acceptable performance in patients with stroke. Our findings support International Consortium for Health Outcomes Measurement recommendation to use PROMIS GH as part of the standard set of outcome measures in stroke.
引用
- Katzan IL, Lapin B. PROMIS GH (Patient-Reported Outcomes Measurement Information System Global Health) Scale in Stroke: A Validation Study. Stroke. 2018. PMID: 29273595. doi:10.1161/STROKEAHA.117.018766
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。